EOCENE LTD
EOCNNASDAQ🏆 #5105 by market capEarnings Nov 24US Equity
$3.23▲ $0.34 (+11.76%)
Latest quoteTrack EOCN
Get earnings, price moves & breaking news on Telegram
24h▲ 11.8%
7d▲ 11.8%
14d▼ 8.0%
30d▼ 12.0%
ytd▼ 47.0%
1y▼ 70.3%
🏦Market Cap
$3M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
1.4x
Cheap
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $2.96 – $3.23
- 52-Week Range
- $2.33 – $4.88
- Volume (shares)
- 391
- Avg Volume (shares)
- —
- Shares Outstanding
- 1.0M
- Next Earnings
- 2026-11-24
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 1.4x
- EPS (TTM)
- $-12.13
- Dividend Yield
- —
EOCENE LTD
EOCNFinancial Trends
Financial history unavailable.
StockOtter · stockotter.spaceAbout EOCENE LTD
Eocene Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
⚖️Valuation★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Sell
6 analysts
Strong Buy0
Buy0
Hold3
Sell1
Strong Sell2
Ratings as of Oct 2026
Latest News & Updates
News unavailable.